Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maternal Oral TUDCA in High-Risk Lactating Mother-Infant Dyads
NCT07517276Phase 2Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Apr 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Maternal Oral TUDCA with Maternal Oral Placebo (2 arms). Primary endpoints: Incidence of maternal treatment-emergent adverse events at 28 days, Incidence of infant treatment-emergent adverse events at 28 days and 1 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
tauroursodeoxycholic acid
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT07517276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07517276.